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PVIEWPOINT
Revisiting the Role of
Oxygen Therapy in Cardiac Patients
Raman Moradkhan, MD, Lawrence I. Sinoway, MD
Hershey, Pennsylvania
Over the past century, multiple studies lacking the precision of today’s advanced technology provided conflicting
data on the effects of oxygen therapy in normoxic cardiac patients. More importantly, no randomized, blinded,
controlled studies have shown a benefit of such treatment. Yet the use of supplemental oxygen is widespread in
cardiac patients. In these conditions, inadvertent hyperoxia commonly occurs because of concerns to ensure
sufficient oxygenation and because hyperoxia is not perceived to be detrimental. In recent years, there has been
mounting evidence demonstrating the potential adverse effects of hyperoxia on the cardiovascular system. In
this report, we review data examining the effects of supplemental oxygen in normoxic patients with acute pre-
sentations of coronary artery disease. It is also the aim of this report to emphasize the point that oxygen therapy
might have major adverse physiologic effects that must be considered when it is employed. (J Am Coll Cardiol
2010;56:1013–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.04.052l
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petween 1940 and 1970, the cardiovascular effects of
yperoxia were extensively investigated. These studies sug-
ested that hyperoxia reduced coronary blood flow (CBF)
1), heart rate, cardiac output/index (1–3), and cardiac
xygen consumption (4), while evoking a rise in blood
ressure, systemic vascular resistance, and the augmentation
ndex, a measure of large artery stiffness (3).
he Rationale for Oxygen Therapy
n Acute Coronary Syndromes
he American College of Cardiology/American Heart As-
ociation task force (ACC/AHA 2007 guidelines) has
ssigned Class I recommendation for oxygen use to correct
rterial oxygen desaturation (SaO2 90%) and Class IIa
ecommendation for all patients with unstable angina/non–
T-segment elevation myocardial infarction and uncompli-
ated ST-segment elevation myocardial infarction within
he first 6 h after presentation. The rationale for oxygen use
s based on 2 assumptions: 1) that increasing arterial oxygen
ension decreases the acute ischemic injury and the eventual
nfarct area (5,6); and 2) the observation that some patients
ith uncomplicated myocardial infarction have arterial hypox-
mia due to fluid retention in the lungs and a ventilation–
erfusion mismatch.
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ccepted April 21, 2010.However, the evidence supporting these assumptions is
imited. Moreover, we are not aware of any studies demon-
trating that normoxic subjects undergoing percutaneous
oronary intervention for acute myocardial infarction derive
ny benefit from supplemental oxygen. Furthermore, there
s no evidence supporting the common practice of oxygen
herapy after successful percutaneous coronary intervention.
Two studies from the 1970s (5,6) were crucial to the
evelopment of the current oxygen therapy guidelines in
cute coronary syndromes (ACS).
Maroko et al. (5) demonstrated in dogs that 40% oxygen
educed electrocardiographic, histological, and biochemical
vidence of myocardial ischemic injury. Unfortunately, the
equence of gas mixture delivery during ventilation was not
andomized and the ST-segment elevation measurements
ere not blinded. Madias and Hood (6) examined the
ffects of supplemental oxygen (delivered via a face mask) in
atients with anterior myocardial infarction. Using precor-
ial ST-segment mapping, these authors noted a 16%
eduction in both the sum of ST-segment elevations and the
umber of recording sites demonstrating ST-segment ele-
ation. However, the study was not randomized, ST-
egment measurements were not blinded, and the timing of
recordial mapping was not standardized. Moreover, the
uration of oxygen inhalation varied greatly among subjects
48 to 80 min).
Rawles and Kenmure (7) performed the first randomized,
ouble-blinded, controlled trial of oxygen therapy in the
etting of uncomplicated myocardial infarction. After ex-
luding 43 patients from the initial 200 subjects, 77 and 80
atients were enrolled in the air and oxygen groups, respec-
ively. Either oxygen or compressed air at a flow rate of
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mask throughout the first 24 h.
Only diamorphine was employed
as medication. All parameters
were comparable except higher
PaO2 and aspartate aminotrans-
ferase levels were noted in the
oxygen group. This study showed
no benefit of oxygen therapy in
reducing arrhythmias or mortal-
ity. On the contrary, supplemen-
al oxygen elevated aspartate aminotransferase levels, sug-
esting infarct expansion. Of note, the mortality rate in the
xygen group was 11.3% compared with 3.9% in the
ontrol group, although this difference was not statistically
ignificant.
oronary Vasoconstriction During Hyperoxia
ecently, duplex ultrasound (HDI 5000, ATL Ultrasound,
othell, Washington) has been employed to measure coro-
ary blood velocity (CBV) (a CBF surrogate) in the left
nterior descending coronary artery of 7 healthy subjects (8).
BV and coronary vascular resistance (CVR) were mea-
ured while breathing room air and after exposure to
yperoxia (100% O2) for 5 min. Hyperoxia decreased CBV
y 15  3% (p  0.01) and raised CVR by 20  4% (p 
.01). Similar findings were observed in 3 cardiac transplant
atients who underwent transplantation 5 to 14 months
arlier (CBV decreased by 16  2% [p  0.01], and CVR
ncreased by 23 3% [p 0.01]) (Figs. 1 and 2), indicating
direct vasoconstrictor effect of hyperoxia on the coronary
irculation not mediated through autonomic reflexes. These
oninvasive observations are consistent with the work of
cNulty et al. (9) who examined the effects of hyperoxia on
he coronary circulation using intracoronary Doppler flow
ire and coronary angiography in stable patients with
oronary arterial disease (coronary stenosis 50% and
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CBF  coronary blood flow
CBV  coronary blood
velocity
CVR  coronary vascular
resistance
Figure 1 Pulsed Doppler Recording of Left Anterior Descending
Blood flow velocity is significantly decreased in both groups during hyperoxia.jection fraction 50%). Hyperoxia decreased CBF by 29%
nd raised CVR by 41% (Fig. 3).
otential Mechanisms of
yperoxic Coronary Vasoconstriction
yperoxia leads to the generation of reactive oxygen
pecies. Mounting evidence supports the hypothesis that
yperoxia leads to the generation of reactive oxygen species,
hich in turn decreases the bioavailability of nitric oxide
nd results in vasoconstriction (10). McNulty et al. (11)
emonstrated that an intravenous infusion of vitamin C (a
otent antioxidant) quickly restores and prevents coronary
asoconstriction during hyperoxia.
he role of KATP channels in hyperoxia-induced
asoconstriction. During hypoxia and ischemia, a fall in
he intracellular ATP concentrations mediates the opening
f ATP-sensitive potassium channels, which in turn causes
nary Artery in Healthy Subjects and Cardiac Transplant Patients
Figure 2 Individual and Mean Responses of CBV and
CVR in Normal Subjects and Transplant Patient
Solid blue arrows indicate normal subjects, and open red arrows indicate
transplant patient. Solid blue and red arrows represent mean values for nor-
mal subjects and the 3 heart transplant patients, respectively. The pressure-
rate product is an index of myocardial O2 consumption. CBV  coronary blood
velocity; CVR  coronary vascular resistance.Coro
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asodilation. Animal studies have shown that KATP chan-
els play an important role in regulating coronary artery
lood flow at rest and during hypoxia and ischemia (12).
ouren et al. (13) demonstrated that hyperoxic coronary
asoconstriction is mediated through the closure of KATP
hannels.
yperoxia can induce vasoconstriction by acting directly
n L-type Ca2 channels. Animal studies (14) demon-
trate that oxygen-sensitive L-type calcium channels are
resent on vascular smooth muscle cells. They contribute to
he local circulatory control during hypoxia and hyperoxia.
yperoxia may affect the release of angiotensin II with
ubsequent changes in endothelin-1 levels. Isolated car-
iac myocyte studies demonstrate that angiotensin I is
roduced with hyperoxia and is subsequently converted to
ngiotensin II, possibly on the surface of endothelial cells.
ngiotensin II promotes endothelin-1 release and thereby
ncreases vascular tone (15).
yperoxia increases the production of potent vasoconstrictor
0-HETE. Hyperoxia induces the production of 20-
ETE, an arachidonic acid metabolite. 20-HETE is a
onstrictor and plays an important role in myogenic regu-
Figure 3 Individual Data for CBF and CVR in Subjects During
Sequential Room Air and 100% Oxygen Breathing
Reproduced with permission from McNulty et al. (9). CBF  coronary blood flow;
CVR  coronary vascular resistance.ation (16).yocardial Oxygen Consumption
uring Hyperoxia
ne could speculate that an increase in oxygen extraction in
CS would compensate for the decreased CBF seen with
xygen. Animal studies suggest that a high PO2 decreases
yocardial oxygen consumption independent of heart rate,
ardiac performance and metabolic requirements. High PO2
ecreases capillary density, which in turn may limit oxygen
iffusion and extraction (17,18). Reinhart et al. (19) con-
rmed that in critically ill patients, high-flow oxygen
herapy causes a misdistribution of microcirculatory blood
ow with increased functional O2 shunting and a reduction
n total-body oxygen consumption (total-body oxygen uptake
ecreased by 10% due to an 18% decrease in O2 extraction).
hus, high-flow oxygen, despite improving oxygenation, may
ot improve organ-specific oxygen delivery.
ummary
e believe that supplemental oxygen is used excessively,
specially in cardiac patients to maintain oxyhemoglobin sat-
rations close to 100%; unknowingly, many of these patients
re exposed to significant periods of hyperoxia. This occurs for
main reasons: 1) many medical staff (including physicians) do
ot recognize that oxygen is a vasoactive substance; 2) when
ranscutanous blood oxyhemoglobin saturation approaches
00%, further increases in blood oxygen tension are not
etected; and 3) oxygen tension is not adequately monitored,
specially in the setting of high-flow oxygen therapy.
Although the use of oxygen is clearly appropriate and
dvisable to treat hypoxia, we hypothesize that excessive use
f supplemental oxygen in normoxic cardiac patients could
otentially lead to worse outcomes in a number of patients.
he current guidelines of oxygen therapy are not based on
andomized, double-blinded, controlled studies. We pro-
ose that such studies are imperative to delineate the precise
ole of oxygen therapy in these conditions. In the interim,
he potential physiologic ramifications of such therapy
hould be considered.
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